Avsola

Avsola (infliximab-axxq) is a biosimilar to Remicade, a widely-prescribed monoclonal antibody that helps the body’s immune system by targeting and destroying certain cells helping to protect healthy cells from damage. Specifically it is a tumor necrosis factor (TNF) blocker used for many chronic inflammatory conditions. Avsola was approved by the FDA in December, 2019 as a biosimilar to Remicade.

For more information, visit the patient website for this drug. Speak with your healthcare provider to learn if this drug is right for you.